TITLE

Reduced Responsiveness to Epoetin at Re-exposure after Prolonged Epoetin-free Period in Anemic Hemodialysis Patients with End-stage Renal Disease

AUTHOR(S)
Milutinović, Slobodan; Trkulja, Vladimir
PUB. DATE
June 2006
SOURCE
Croatian Medical Journal;2006, Vol. 47 Issue 3, p424
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aim To determine if temporary discontinuation of epoetin therapy in anemic patients with end stage renal disease (ESRD) influences their responsiveness to epoetin. Methods We performed a post hoc analysis of the data from two consecutive single-center randomized trials (T1 and T2) comparing the efficacy of two epoetin products (E1 and E2) in anemic patients with ESRD. The analysis included a subset of 44 patients who participated in both trials and were not receiving epoetin in the period (median, 12 months; range 5-15) between the trials due to epoetin shortage. Two co-primary outcomes were average weekly hemoglobin difference from the baseline and average weekly epoetin dose. Results With adjustment for potential differences between E1 and E2, average weekly hemoglobin difference of 1.21 g/dL from the baseline was lower in T2 than that of 1.71 g/dL in T1: difference -0.49 (95% confidence interval [CI], -0.68 to -0.29; P<0.001). Average weekly epoetin dose of 107 IU/kg in T2 was higher than 96 IU/kg in T1 (ratio, 1.13; 95% CI, 1.04-1.24; P = 0.009). With additional adjustment for within-subject changes in baseline covariates from T1 to T2 (baseline hemoglobin, body mass index, serum albumin, ferritin and transferrin saturation, intact parathormone, C-reactive protein, dialysis dose, and use of angiotensin converting enzyme inhibitors), hemoglobin response remained lower (adjusted difference, -0.44 g/dL; 95% CI, -0.73 to -0.16; P = 0.004) and weekly epoetin dose remained higher in T2 than inT1 (adjusted ratio, 1.17; 95% CI, 1.03-1.34; P = 0.016). Conclusions In patients with ESRD, responsiveness to epoetin was lower in T2 after a period of epoetin therapy discontinuation than in T1 epoetin trial. Since this could not be explained by within-subject changes in factors known to affect response to epoetin, a prolonged withdrawal of epoetin in patients with ESRD might independently contribute to a reduced responsiveness to epoetin at a later re-exposure.
ACCESSION #
21416991

 

Related Articles

  • Anemia Management Protocols: Providing Consistent Hemoglobin Outcomes. Michael, Maureen // Nephrology Nursing Journal;Jul/Aug2005, Vol. 32 Issue 4, p423 

    Anemia management protocols encourage a consistent therapeutic approach that can increase the likelihood of patients achieving and maintaining stable hemoglobin levels within the target range of 11 to 12 g/dL recommended by the National Kidney Foundation. This article provides an overview of...

  • Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article focuses on a phase two study of AKB-6548 in the patients with stage three and four chronic kidney disease (CKD), conducted and completed by Akebia Therapeutics Inc. The AKB-6548 is an orally bioavailable hypoxiainducible factor-prolyl hydroxylase (HIF-PH) inhibitor which aids in the...

  • Variability in Hemoglobin Levels: Clinical Implications. Candela, Julianna M.; Dutka, Paula; Bennett, Jennifer; Holland, Maureen; Donahue, Christine; Delorme, Jean; Lynn, Robert // Nephrology Nursing Journal;Oct2001, Vol. 28 Issue 5, p567 

    Provides information on a study that determined the impact of hemoglobin variability on the interpretation of anemia management outcomes in hemodialysis patients. Methodology of the study; Results and discussion on the study; Conclusions.

  • Hemoglobin Variability: Managing the Higher End of the Target Range. Breiterman-White, Randee // Nephrology Nursing Journal;Mar/Apr2007, Vol. 34 Issue 2, p201 

    Management of patients at both the lower and the upper ranges of the hemoglobin target range is crucial to ensuring optimal anemia-related outcomes in patients on dialysis. Nurses can be instrumental in helping to minimize the percentage of patients with hemoglobin levels above the target range...

  • Frequency distribution of sickle cell anemia, sickle cell trait and sickle/beta-thalassemia among anemic patients in Saudi Arabia. Elsayid, Mohieldin; Al-Shehri, Mohammed Jahman; Alkulaibi, Yasser Abdullah; Alanazi, Abdullah; Qureshi, Shoeb // Journal of Natural Science, Biology & Medicine;2015 Supplement, pS85 

    Background: Notwithstanding, the growing incidence of sickle cell hemoglobinopathies (SCH) such as sickle cell anemia (SCA) or sickle cell disease, sickle/beta-thalassemia; the exact prevalence remains obscure in Saudi Arabia. Hence, this study is an attempt to determine the frequency of SCA and...

  • Erythropoietin use in critically ill patients: forest and trees. Corwin, Howard L. // CMAJ: Canadian Medical Association Journal;9/25/2007, Vol. 177 Issue 7, p747 

    The article presents the author's views on the role of erythropoientin in severely ill patients. The author says that circulation of erythropoietin concentrations stop in patients with anemia which results in low hemoglobin. The haemoglobin concentration is increased in critically ill patients...

  • Every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia. Goram, Adrian L. // American Journal of Health-System Pharmacy;8/15/2006, Vol. 63 Issue 16, p1522 

    Purpose. The effectiveness of every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia was evaluated. Methods. Women receiving chemotherapy for gynecological tumors who had a hemoglobin concentration of <10 g/dL were recruited from an obstetrics and...

  • Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Hanafusa, Norio; Nomura, Takanobu; Hasegawa, Takeshi; Nangaku, Masaomi // Nephrology Dialysis Transplantation;Dec2014, Vol. 29 Issue 12, p2316 

    Background The elderly hemodialyzed population is growing. However, little is known about the relationship between hemoglobin level and survival according to age. We investigated the effect of age on the relationship between hemoglobin and survival within the Japan Dialysis Outcomes and Practice...

  • Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease. Chutia, Happy; Ruram, Alice Abraham; Bhattacharyya, Himashree; Boruah, Polina; Nath, Chandan // Journal of Laboratory Physicians;Jan-Jun2013, Vol. 5 Issue 1, p51 

    Purpose: Secondary hyperparathyroidism (SHPT) is one of the less recognized reasons of anemia in chronic kidney disease (CKD). In this study, we evaluated the role of SHPT as a cause of anemia and correlation of intact parathyroid hormone (iPTH) and hemoglobin (Hb) level in hemodialysis (HD)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics